despite a diagnosis of CaP. Furthermore, our data demonstrate a

lower rate of CaP recurrence in men on TRT than the published

recurrence rate for men with CaP not treated with TRT. However,

in the continued absence of randomized controlled trial data, TRT

in patients with CaP should be undertaken with appropriate

follow-up.

CONFLICT OF INTEREST

The authors declare the following potential conﬂict of interest. Mohit Khera: Slate

Pharmaceuticals—consultant; Auxilium Pharmaceuticals—speaker, research support;

Merck—consultant. Larry I Lipshultz: Auxilium Pharmaceuticals—consultant, speaker,

research support; Allergan Pharmaceuticals—research support. The other authors

declare no conﬂict of interest.

REFERENCES

1 Araujo AB, Esche GR, Kupelian V, O’Donnell AB, Travison TG, Williams RE

et al.

Prevalence of symptomatic androgen de±ciency in men.

J Clin Endocrinol Metab

2007;

: 4241–4247.

2 Census UBot. Age and sex composition: 2010Census UBot: Washington, DC, 2011.

3 Society TE. The Endocrine Society.

Summary from the 2nd Annual Andropause

Consensus Meeting

Chevy Chase, MD 2001.

4 Traish AM, Guay A, Feeley R, Saad F. The dark side of testosterone de±ciency: I.

Metabolic syndrome and erectile dysfunction.

J Androl

2009;

: 10–22.

5 Traish AM, Saad F, Feeley RJ, Guay A. The dark side of testosterone de±ciency: III.

Cardiovascular disease.

J Androl

2009;

: 477–494.

6 Traish AM, Saad F, Guay A. The dark side of testosterone de±ciency: II. Type 2

diabetes and insulin resistance.

J Androl

2009;

: 23–32.

7 Huggins C, Hudges CV. Studies on prostatic cancer. I. The effect of castration, of

estrogen and androgen injection on serum phosphatases in metastatic carcinoma

of the prostate.

Cancer Res

1941;

: 293–297.

8 Arnold JT, Le H, McFann KK, Blackman MR. Comparative effects of DHEA vs tes-

tosterone, dihydrotestosterone, and estradiol on proliferation and gene expres-

sion in human LNCaP prostate cancer cells.

Am J Physiol Endocrinol Metab

2005;

288

: E573–E584.

9 Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary

treatment for prostate cancer.

J Urol

2005;

173

: 533–536.

10 Kaufman JM, Graydon RJ. Androgen replacement after curative radical prosta-

tectomy for prostate cancer in hypogonadal men.

J Urol

2004;

172

: 920–922.

11 Khera M, Grober ED, Najari B, Colen JS, Mohamed O, Lamb DJ

et al.

Testosterone

replacement therapy following radical prostatectomy.

JSexMed

2009;

: 1165–1170.

12 Morales A, Black AM, Emerson LE. Testosterone administration to men with tes-

tosterone de±ciency syndrome after external beam radiotherapy for localized

prostate cancer: preliminary observations.

BJU Int

2009;

103

:62–64

13 Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early

prostate cancer with brachytherapy.

Cancer

2007;

109

: 536–541.

14 Morales A. Effect of testosterone administration to men with prostate cancer is

unpredictable: a word of caution and suggestions for a registry.

BJU Int

2011;

107

1369–1373.

15 Ferreira U, Leitao VA, Denardi F, Matheus WE, Stopiglia RM, Netto Jr. NR. Inter-

mittent androgen replacement for intense hypogonadism symptoms in castrated

patients.

Prostate Cancer Prostatic Dis

2006;

: 39–41.

16 Morgentaler A, Lipshultz LI, Bennett R, Sweeney M, Avila Jr. D, Khera M.

Testosterone therapy in men with untreated prostate cancer.

J Urol

2011;

185

1256–1260.

17 Leibowitz RL, Dorff TB, Tucker S, Symanowski J, Vogelzang NJ. Testosterone

replacement in prostate cancer survivors with hypogonadal symptoms.

BJU Int

2010;

105

: 1397–1401.

18 Jannini EA, Gravina GL, Morgentaler A, Morales A, Incrocci L, Hellstrom WJ. Is

testosterone a friend or a foe of the prostate?

J Sex Med

2011;

: 946–955.

19 NCCN. Prostate Cancer 2012. http://www.nccn.org.

20 Daniell HW, Clark JC, Pereira SE, Niazi ZA, Ferguson DW, Dunn SR

et al.

Hypo-

gonadism following prostate-bed radiation therapy for prostate carcinoma.

Cancer

2001;

: 1889–1895.

21 Pickles T, Graham P. What happens to testosterone after prostate radiation

monotherapy and does it matter?

J Urol

2002;

167

: 2448–2452.

22 Zagars GK, Pollack A. Serum testosterone levels after external beam radiation for

clinically localized prostate cancer.

Int J Radiat Oncol Biol Phys

1997;

: 85–89.

23 Kinsella TJ. Effects of radiation therapy and chemotherapy on testicular function.

Prog Clin Biol Res

1989;

302

: 157–171(discussion 172–157).

24 Grigsby PW, Perez CA. The effects of external beam radiotherapy on endocrine

function in patients with carcinoma of the prostate.

J Urol

1986;

135

: 726–727.

25 Taira AV, Merrick GS, Galbreath RW, Butler WM, Lief JH, Allen ZA

et al.

Serum

testosterone kinetics after brachytherapy for clinically localized prostate cancer.

Int J Radiat Oncol Biol Phys

2012;

: e33–e38.

26 Tomic R, Bergman B, Damber JE, Littbrand B, Lofroth PO. Effects of external

radiation therapy for cancer of the prostate on the serum concentrations of

testosterone, follicle-stimulating hormone, luteinizing hormone and prolactin.

J Urol

1983;

130

: 287–289.

27 Miller LR, Partin AW, Chan DW, Bruzek DJ, Dobs AS, Epstein JI

et al.

Inﬂuence of

radical prostatectomy on serum hormone levels.

J Urol

1998;

160

: 449–453.

28 Lukkarinen O. Total and SHBG-bound testosterone and 5 alpha-dihydrotesto-

sterone serum concentrations in normal elderly men and patients with benign

prostatic hypertrophy before and after removal of the adenoma.

Br J Urol

1980;

: 377–380.

29 Ghanadian R, Puah CM, Williams G, Shah PJ, McWhinney N. Suppressive effects of

surgical stress on circulating androgens during and after prostatectomy.

Br J Urol

1981;

: 147–149.

30 McCullough AR, Khera M, Goldstein I, Hellstrom WJ, Morgentaler A, Levine LA.

A Multi-institutional observational study of testosterone levels after testosterone

pellet (Testopel(R)) insertion.

J Sex Med

2012;

: 594–601.

31 Kattan MW, Potters L, Blasko JC, Beyer DC, Fearn P, Cavanagh W

et al.

Pretreat-

ment nomogram for predicting freedom from recurrence after permanent pros-

tate brachytherapy in prostate cancer.

Urology

2001;

: 393–399.

32 Shipley WU, Thames HD, Sandler HM, Hanks GE, Zietman AL, Perez CA

et al.

Radiation therapy for clinically ocalized prostate cancer: a multi-institutional

pooled analysis.

JAMA

1999;

281

: 1598–1604.

33 Pollack A, Hanlon AL, Movsas B, Hanks GE, Uzzo R, Horwitz EM. Biochemical failure

as a determinant of distant metastasis and death in prostate cancer treated with

radiotherapy.

Int J Radiat Oncol Biol Phys

2003;

: 19–23.

34 Holzman M, Carlton Jr. CE , Scardino PT. The frequency and morbidity of local

tumor recurrence after de±nitive radiotherapy for stage C prostate cancer.

J Urol

1991;

146

: 1578–1582.

35 Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate

cancer: the saturation model and the limits of androgen-dependent growth.

Eur Urol

2009;

: 310–320.

36 Horwitz EM, Thames HD, Kuban DA, Levy LB, Kupelian PA, Martinez AA

et al.

De±nitions of biochemical failure that best predict clinical failure in patients with

prostate cancer treated with external beam radiation alone: a multi-institutional

pooled analysis.

J Urol

2005;

173

: 797–802.

37 Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R

et al.

Combined

androgen deprivation therapy and radiation therapy for locally advanced prostate

cancer: a randomised, phase 3 trial.

Lancet

2011;

378

: 2104–2111.

38 Bachman E, Feng R, Travison T, Li M, Olbina G, Ostland V

et al.

Testosterone

suppresses hepcidin in men: a potential mechanism for testosterone-induced

erythrocytosis.

J Clin Endocrinol Metab

2010;

: 4743–4747.

39 Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmaco-

kinetics ef±cacy, and safety of a permeation-enhanced testosterone transdermal

system in comparison with bi-weekly injections of testosterone enanthate for the

treatment of hypogonadal men.

J Clin Endocrinol Metab

1999;

: 3469–3478.

40 Kaminetsky JC, Moclair B, Hemani M, Sand M. A phase IV prospective evaluation

of the safety and ef±cacy of extended release testosterone pellets for the treat-

ment of male hypogonadism.

J Sex Med

2011;

: 1186–1196.

41 Vicini FA, Shah C, Kestin L, Ghilezan M, Krauss D, Ye H

et al.

Identifying differences

between biochemical failure and cure: incidence rates and predictors.

Int J Radiat

Oncol Biol Phys

2011;

: e369–e375.

Testosterone replacement after radiation treatment for prostate cancer

AW Pastuszak

et al

International Journal of Impotence Research (2013), 24 – 28

2013 Macmillan Publishers Limited